Watch for Amputation Warnings With Diabetes Med Invokana
A new warning about amputation with canagliflozin (Invokana, etc) will have patients asking about the safety of SGLT2 inhibitors.
This is the latest in a growing list of flozin concerns...ketoacidosis, acute kidney injury, UTIs, yeast infections, etc.
Amputations, mainly of the toe or mid-foot, are seen in about 6 in 1,000 patients taking canagliflozin per year...compared to about 3 in 1,000 patients per year on other diabetes meds.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote